UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 15, 2003
MANHATTAN PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware 000-27282 36-3898269
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
787 Seventh Avenue, 48th Floor
New York, New York 10019
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (212) 554-4525
(Former Name or Former Address, if Changed Since Last Report)
ITEM 5. OTHER EVENTS AND REQUIRED FD DISCLOSURE.
In accordance with the provisions of paragraph (d) of Rule 135c
promulgated under the Securities Act of 1933, as amended, the Registrant has
attached hereto as Exhibit 99.1 is its Preliminary Notice of Action to Be Taken
by Written Consent of Stockholders in Lieu of a Special Meeting and Information
Statement on Schedule 14C, which was filed with the Commission on August 15,
2003.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) Exhibits
99.1 Registrant's Preliminary Notice of Action to Be Taken
by Written Consent of Stockholders in Lieu of a
Special Meeting and Information Statement on Schedule
14C.
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
MANHATTAN PHARMACEUTICALS, INC.
Date: August 15, 2003 By: /s/ Nicholas J. Rossettos
-----------------------------
Chief Operating Officer and
Chief Financial Officer
2
EXHIBIT INDEX
99.1 Registrant's Preliminary Notice of Action to Be Taken by
Written Consent of Stockholders in Lieu of a Special Meeting
and Information Statement on Schedule 14C.